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Introduction
Following the implementation of preoperative treatment, it has become apparent that rectal cancer response to chemoradiotherapy (CRT) varies considerably, ranging from complete tumor disappearance to lack of response, or even disease progression [1] . Early variables to assess tumor response, such as downsizing, downstaging, and tumor regression grading (TRG), have been proposed to reflect tumor biology, treatment efficacy, and patients' prognosis [2, 3] and may be used as surrogates for disease-free survival (DFS) and overall survival (OS).
The interest in early surrogate end points has grown considerably in oncology trials [4, 5] . Surrogate end points are early indirect measures of true clinical end points and can decrease the number of patients and time needed to complete a trial, enabling early and less costly assessment of the benefit of experimental treatments [6] . The establishment of surrogate markers poses a challenge as it requires rigorous statistical validation using large trial datasets. Also, whether surrogate end points reflect true clinical benefit is discussed controversially [4, 5] . In that context, the neoadjuvant rectal (NAR) score has been recently proposed by the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group (NRG) Oncology to serve as a potential surrogate for clinical end points in trials testing preoperative treatment in rectal cancer The NAR score was developed on the basis of Valentini's nomograms for OS [7] incorporating a weighted combination of the pre-CRT cT-category, and post-CRT ypT and ypN categories and represents a pseudocontinuous variable with 24 possible discrete scores, ranging from 0 to 100 [8] . In the NSABP R-04 trial, the NAR score was classified as low (NAR < 8), intermediate , and high (NAR > 16) according to the tertiles of the observed scores, and lower NAR score was associated with better OS [8] .
We investigated the prognostic value of NAR score in the CAO/ARO/AIO-04 randomized phase III trial. In that trial, the addition of oxaliplatin to 5-fluorouracil (5-FU)-based preoperative CRT resulted in a significant improvement of the primary end point, DFS, compared with the standard arm [9, 10] . The aims of the present work were (i) to examine the prognostic role of the NAR score and (ii) to assess whether the NAR score constituted an individual-level surrogate for DFS according to the Prentice criteria (PC) that had been used to confirm that the treatment effect on the surrogate end point reflects the treatment effect on the clinical end point [11] .
Patients and methods

Study design and participants
The CAO/ARO/AIO-04 trial (ClinicalTrials.gov, number NCT00349076) was a multicenter, open-label, two-arm randomized phase III study. The design, treatment plan, and clinical outcome have been described before [9, 10] . The trial received approval by the ethics committee of the University of Erlangen, Germany. A þdescription of the design, pretreatment, and pathologic examination, and follow-up is shown in supplementary Methods, available at Annals of Oncology online; supplementary Figure S1 , available at Annals of Oncology online illustrates the treatment plan. The full trial protocol is provided as supplementary material, available at Annals of Oncology online.
NAR score
The NAR score incorporates cT to account for tumor downstaging, and ypT and ypN that are influenced directly by preoperative treatment [8] . The NAR formula is as follows: NAR ¼ [5 pN-3(cT-pT)þ12] 2 /9.61, where cT in {1, 2, 3, 4}, pT in {0, 1, 2, 3, 4} and pN in {0, 1, 2}. NAR consists of 24 distinct scores that range from 0 to 100. For ypT category and ypN category, a relative weight of 3 and 5 was suggested to reflect the impact of these variables, based on the nomogram of Valentini [7] . The constant 12 is included to maintain all scores inside the brackets as positive. The scaling factor 9.61 was introduced to ensure that the final scores range from 0 to 100.
Statistical analysis
The statistical analyses are described in detail in supplementary Methods, available at Annals of Oncology online.
Results
Patient characteristics and association of NAR with clinicopathologic factors
Between July 2006 and February 2010, 1265 patients were recruited in the trial (CONSORT, supplementary Figure S2 , available at Annals of Oncology online). A total of 607 patients were actually treated with fluorouracil plus oxaliplatin-based preoperative CRT (5-FU/OX-CRT), and 625 patients actually received fluorouracil alone during CRT (5-FU-CRT). The NAR score was available in a total of 1191 patients, and Table 1 shows the results after both treatments. 5-FU/OX-CRT led to a statistically significant shift toward lower NAR scores as compared with 5-FU-CRT (P ¼ 0.034). The sample tertiles in the CAO/ARO/ AIO-04 study population were similar to the NAR cut-offs of 8 and 16, as reported in the NSABP R-07 trial (supplementary Table S1 , available at Annals of Oncology online).
Regarding pretreatment clinicopathologic characteristics (supplementary Table S2 , available at Annals of Oncology online), the proportion of patients with higher NAR scores was significantly increased in patients with age median, cNþ, and less differentiated tumors. Also, NAR was significantly associated with several pathologic factors after preoperative CRT and surgery, including completeness of surgical resection, ypT category, ypN category, pathologic Union internationale contre le cancer (UICC)-stage, circumferential resection margin involvement (CRMþ) and a longer median interval between completion of preoperative CRT and surgery (supplementary Table S3 , available at Annals of Oncology online). The latter reflects the shifting toward lower ypT categories and is in accordance with previous studies showing that longer waiting periods between CRT completion and surgery led to increased tumor regression [12, 13] .
The prognostic role of NAR for clinical outcomes
The median follow-up was 50 months (interquartile range ¼ 38-61 months) ( Table 2 ). In univariate analysis (Table 2; Figure 1 ) lower NAR score was significantly associated with better 3-year cumulative incidence of DFS, local recurrence, distant metastasis and OS (all P < 0.001). We examined the prognostic significance of treatment arms and the clinicopathologic parameters in univariate analysis (Table 2) . A significantly improved DFS (P ¼ 0.034) and local control (P ¼ 0.020) were observed following addition of oxaliplatin to 5-FU-based CRT. Patients with complete surgical resection had significantly better DFS (P ¼ 0.014) and OS (P < 0.001), whereas pathologic stage correlated with all four clinical end points (P < 0.001 in each case). CRM showed statistical significance for DFS (P < 0.001), cumulative incidence of distant metastasis (P < 0.001), local recurrence (P < 0.001), and OS (P¼ .036). Older patients had significantly worse OS (P ¼ 0.001).
We next conducted a multivariable analysis for all four clinical end points (Table 3 ). Due to multicollinearity that could lead to statistical bias, NAR and pathologic UICC stage could not be tested within the same model. Also, we excluded CRM as several cases were either missing or unknown. Low versus high NAR score constituted an independent prognostic factor for DFS (P < 0.001), the cumulative incidence of local recurrence (P ¼ 0.002), the cumulative incidence of distant metastases (P< 0.001), and OS (P < 0.001). Similar significant findings were observed for low versus intermediate NAR score with regard to all clinical end points with the exception of local recurrence (P ¼ 0.068) in multivariable analysis. Complete resection (R0) predicted for better DFS (P <0.001), cumulative incidence of distant metastases (P ¼ 0.005), and OS (P < 0.001). The experimental treatment arm was associated with better local control (P ¼ 0.021) ( Table 3) .
NAR as a surrogate marker for DFS
We evaluated the surrogacy of NAR score for DFS at an individual-patient level based on the four Prentice criteria [11] : PC 1 (significant treatment effect on DFS, P ¼ 0.034; Table 2 ), PC 2 (significant impact of treatment arm on NAR, P ¼ 0.034, Table 1 ), and PC 3 (significant association between NAR score and DFS, P < 0.001; Table 2 ) were fulfilled. PC 4 necessitates that the significant effect of the treatment arms on the primary end point DFS disappears once the surrogate is accounted for. The assessment for PC 4 was based on a Cox model for DFS with treatment arm and NAR included. The previously significant treatment effect on DFS (P ¼ 0.034) as shown in Table 2 has now vanished from this model [hazard ratio (HR) 0.880, 95% confidence interval [CI] 0.693-1.116, P ¼ 0.292), while the significant impact of NAR score (low versus high) on DFS was retained (HR ¼ 3.855; 95% CI 1.879-7.909; P < 0.001). Therefore, the treatment effect on DFS was captured by the NAR score, satisfying PC 4. Additional sensitivity analyses were conducted to demonstrate the surrogacy of NAR for DFS based on PC 4 (supplementary Methods and Results and Figure S3 , available at Annals of Oncology online) [14] .
Discussion
The NAR score has been proposed by the NRG Oncology as a primary end point to assess preoperative treatment efficacy in clinical trials in rectal cancer [8, 15] . The NAR score was prognostic for OS in a retrospective series [16] and the NSABP-R04 phase III trial dataset for the entire study cohort but analysis according to treatment arms was not carried out [8] . The basic hypothesis is that changes in mean NAR scores between neoadjuvant treatment interventions should translate to changes in DFS or OS. The NAR score retained an independent prognostic value for the primary end point, DFS, in multivariable analysis in the CAO/ARO/AIO-04 randomized phase III trial.
Appropriate surrogate end points in trials depend on the clinical context and require careful interpretation [17] . Surrogate end points in rectal cancer are lacking as their statistical validation poses major challenges, including confirmation in large trial data sets. In our study, the four PC [11] regarding the individual-level surrogacy of NAR for DFS were met. Several trials have used the PC in the recent years for assessment of potential surrogates [17] [18] [19] [20] [21] . It should be noted that the PC 4 is characterized by inherent difficulties in its interpretation that constitutes a methodological limitation in establishing surrogacy, and alternative methods have been proposed by Buyse et al. [6, 22, 23] . Also, assessment of NAR effects based on meta-analysis of large randomized trials is a prerequisite for the validation of its surrogacy at both the individual and trial levels [6] , extending beyond the PC. Nevertheless, our large phase III trial in rectal cancer confirms the individual-level surrogacy of NAR score for DFS and corroborates its use as primary end point in (early) clinical trials, such as the NRG-GI002 using radiosensitizers [24] , to speed up evaluation of efficacy and access of new treatments. Other alternative early surrogate end points have been proposed, such as downsizing, downstaging, sterilizing lymph nodes, pathologic complete response (pCR), TRG, CRM involvement, R0 or sphincter sparing resections [25] [26] [27] . The strength of the NAR score is the incorporation of both pre-and post-CRT variables to reflect initial tumor extent and tumor response. Weighing these variables based on their relative importance results in 24 possible discrete scores rather than in a dichotomized end point, 90.9 (73.9 to 100) <0.001 0 (0 to 0) <0.001 4.5 (0 to 13.5) <0.001 83.5 (60.4 to 100) <0.001
The log-rank test was used to calculate statistical significance stratified by treatment arm. The cumulative incidence of locoregional and distant recurrences was assessed considering death as competing risk. The statistical test was two sided. a With regard to postsurgical pathologic parameters, all clinical end points were calculated from date of surgery to prevent length bias. b For DFS and cumulative incidence of local recurrence, R2 an event.
Significant P-values (P<0.05) are in bold. DFS, disease-free survival; OS, overall survival; 5-FU, 5-fluorouracil; CRT, chemoradiotherapy; OX, oxaliplatin; pCR, pathologic complete response; NAR, neoadjuvant rectal; CI, confidence interval; n.a., not applicable.
as in the case of downstaging, pCR, CRM, R0. A shift of the pseudo-continuous NAR scores induced by different neoadjuvant interventions likely reflects treatment effects more accurately compared with binary end points. TRG has also been proposed to stratify tumor response to CRT and predict prognosis [3, 28, 29] , but histopathologic standardization is lacking [30] . pCR correlates with survival after neoadjuvant treatment in breast cancer and the FDA allowed its use as surrogate end point for accelerated approval process [31, 32] . However, in rectal cancer, the role of pCR remains controversial and depends on several factors, such as the dose and the schedule of radiotherapy, combination with chemotherapy, and the time between treatment and surgery [26, 33, 34] . Yothers et al. showed that the NAR score had greater predictive ability than pCR for OS [35] . Finally, parameters such as the quality of total mesorectal excision can affect clinical outcome that could impact NAR and, hence, variability in quality assurance among trials should be considered when assessing the surrogacy of NAR for OS or DFS.
We would like to acknowledge the limitations of our work. First, assessment of the prognostic value and surrogacy of NAR score was done post hoc. Second, magnetic resonance imaging was not mandatory for baseline staging that could have affected the NAR score, considering the uncertainty of ultrasound when assessing cT and cN category. Third, central pathologic review was not conducted. Fourth, confirmation of PC 4 is discussed controversially due to the abovementioned inherent methodological limitations Figure 1 . Prognostic significance of NAR score after preoperative chemoradiotherapy and TME surgery in rectal carcinoma. Prognostic significance of NAR for (A) disease-free survival; (B) cumulative incidence of local recurrence; (C) cumulative incidence of distant metastases; and (D) overall survival. Please note the different numbers at risk shown below each graph, according to the different clinical end point definition and available follow-up. Statistical significance was examined using the log-rank test, stratified by treatment arm and the statistical test was two sided. In univariate analysis, the cumulative incidence of locoregional and distant recurrences was analyzed with death as competing risk, whereas all.
in establishing surrogacy, and alternative methods have been proposed [6, 14, 36] that should be taken into account. Fifth, analyses were done on the individual-level only. Sixth, the NAR score was developed based on Valentini nomogram for OS, whereas in the current study, we assessed the surrogacy of NAR for DFS as the latter constituted the primary clinical end point. Altogether, our results corroborate the NRG Oncology strategy to use the NAR score as the primary end point in early phase rectal cancer trials including induction chemotherapy and molecular therapies. The NAR score constitutes an easily usable end point that can predict treatment effects and help oncologists to speed up response-adapted individualized therapeutic decisions in the era of personalized medicine. These data pave the path for further validation of the NAR score in large phase III trial datasets to confirm trial-level surrogacy. Multivariable analyses were conducted using the Cox model for DFS and OS, and the Fine-Gray model for cumulative incidence of locoregional and distant recurrences. The statistical test was two-sided. We first fitted Cox (or Fine-Gray) models with treatment arm and completeness of local resection. We then added NAR to this model, but kept the regression parameters for treatment arm and completeness of local resection fix (thus, the effect of NAR now describes the additional information contained in NAR). Empty spaces appear as "-"per definition of the end points. b Patients with R2-resection were also included in the multivariable analysis for cumulative incidence of distant metastases and overall survival.
Significant P-values (P<0.05) are in bold. DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; 5-FU, 5-fluorouracil; OX, oxaliplatin; CRT, chemoradiotherapy; NAR, neoadjuvant rectal.
